Cannara Biotech (LOVFF) Stock Statistics & Valuation Metrics

Cannara Biotech has a market cap or net worth of $109.50M. The enterprise value is $149.75M.

Cannara Biotech has 91,433,136 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cannara Biotech’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Cannara Biotech is 9.7. Cannara Biotech’s PEG ratio is 0.00.

In the last 12 months, Cannara Biotech had revenue of 107.32M and earned 13.08M in profits. Earnings per share was 0.14.

In the last 12 months, operating cash flow was 19.18M and capital expenditures -6.36M, giving a free cash flow of 12.82M billion.

Cannara Biotech pays an annual dividend of ―, resulting in a dividend yield of ―

Cannara Biotech upcoming earnings date is Jan 26, 2026, Before Open (Confirmed).

Cannara Biotech as a current ratio of ―, with Debt / Equity ratio of 48.15%

In the past 12 months, Cannara Biotech has paid 5.02M in taxes.

Cannara Biotech EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Cannara Biotech has $14.36M in cash and marketable securities with $41.58M in debt, giving a net cash position of -$27.22M billion.

Gross margin is 44.57%, with operating margin of ―, and net profit margin of ―.

The average price target for Cannara Biotech is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy